ABCAM Plc Directors' dealings: Deferred Share Award (2693W)

TIDMABC

RNS Number : 2693W

ABCAM Plc

05 November 2014

 
 For immediate release   5 November 2014 
 

ABCAM PLC

("Abcam" or "the Company")

Director dealing: Abcam plc Annual Bonus Plan - Deferred Share Award

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools announces that following approval by the Remuneration Committee, Deferred Share Awards in the form of Nil Cost Options or Conditional Shares (the "Award") have today been granted to the following Directors under the Abcam plc Annual Bonus Plan (the "Plan") in respect of the financial year ended 30 June 2014:

 
 Director           Number of 
                     0.2 pence 
                     Ordinary 
                     Shares subject 
                     to the Award 
 Alan Hirzel            10,538* 
                   ---------------- 
 Jim Warwick            12,453 
                   ---------------- 
 Jeff Iliffe            12,453 
                   ---------------- 
 Jonathan Milner        17,243 
                   ---------------- 
 

* The award made to Alan Hirzel is in the form of conditional shares which will be delivered following vesting.

The Award will vest on 23 September 2016.

For further information please contact:

 
 Abcam                                     + 44 (0) 1223 696 000 
 Jeff Iliffe, Chief Financial Officer 
 Numis Securities - Nominated Adviser 
  & Joint Broker                           + 44 (0) 20 7260 1000 
 Michael Meade - Nominated Adviser 
 James Black - Corporate Broking 
 Peel Hunt LLP - Joint Broker              + 44 (0) 20 7418 8900 
 Clare Terlouw / Jock Maxwell MacDonald 
 Brunswick                                 + 44 (0) 20 7404 5959 
 Justine Mcllroy / Robin Wrench 
 

Notes for editors:

About Abcam plc

Abcam plc is a leading provider of life science research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices enabling local services, multi-language support and sells to over 100 countries. The Company was founded in 1998, and now employs over 740 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcamplc.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBABFTMBTMBTI